TNFSF10 and familial pancreatic carcinoma: We examined the antitumor effect of TRAIL on the six TRAIL-insensitive pancreatic cancer cell lines when combined with orally bioavailable Bcl-2 inhibitors, ABT-199 or ABT-263 (Figure 2B).